Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: This systematic review and meta-analysis aimed to compare extended-release naltrexone (XR-NTX) and oral naltrexone (NTX) for treating substance use disorders (SUDs).
Methods: A comprehensive search of multiple databases (MEDLINE, Embase, Cochrane, APA PsycInfo, and Scopus) was conducted on October 1, 2024, with no date or language restrictions. Inclusion criteria were adults with SUDs, interventions with XR-NTX, comparisons with oral NTX, and outcomes on treatment persistence, hospitalizations, and emergency department (ED) visits. Randomized controlled trials (RCTs) and observational studies were included. Odds ratios were calculated using the Mantel-Haenszel random-effects model.
Results: Of the 1116 studies screened, 27 were selected for full-text review, 15 met the inclusion criteria (3 open-label RCTs [n = 340] and 12 retrospective studies [n = 18,695]) focusing on alcohol use disorder (AUD) and opioid use disorder (OUD), and 7 were included in the meta-analysis. We found no other SUD where the two interventions were compared. Treatment persistence was significantly higher with XR-NTX compared to oral NTX at both 3 months (OR 1.43 [95 % CI: 1.04-1.96], p = 0.03) and 6 months (OR 1.96 [95 % CI: 1.37-2.81], p = 0.0002). No significant differences were observed in healthcare utilization, including inpatient admissions (OR 0.69 [95 % CI: 0.30-1.61], p = 0.39) or ED visits (OR 1.17 [95 % CI: 0.61-2.26], p = 0.63).
Conclusions: Patients with AUD and OUD receiving XR-NTX stay in treatment longer than those receiving oral NTX. However, hospitalization and ED visit rates did not differ. Findings are limited due to a small number of RCTs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289340 | PMC |
| http://dx.doi.org/10.1016/j.drugalcdep.2025.112789 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.
Nature
August 2025
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Perineural invasion (PNI) is a well-established factor of poor prognosis in multiple cancer types, yet its mechanism remains unclear. Here we provide clinical and mechanistic insights into the role of PNI and cancer-induced nerve injury (CINI) in resistance to anti-PD-1 therapy. Our study demonstrates that PNI and CINI of tumour-associated nerves are associated with poor response to anti-PD-1 therapy among patients with cutaneous squamous cell carcinoma, melanoma and gastric cancer.
View Article and Find Full Text PDFAcupoint Catgut Embedding at Stellate Ganglion Combined with Oral Mecobalamin Versus Mecobalamin Monotherapy in Managing Taxane-Induced Peripheral Neurotoxicity: A Clinical Observational Study.
Int J Gen Med
August 2025
Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150086, People's Republic of China.
Purpose: Taxane-induced peripheral neurotoxicity (TIPN) severely impacts the quality of life of patients and worsens over time with cumulative drug exposure. This study aims to evaluate the efficacy and safety of Stellate Ganglion Catgut Embedding (SGCE) therapy in treating TIPN patients, exploring a novel approach to managing TIPN.
Patients And Methods: The study was conducted from June 2023 to June 2024 at the Second Affiliated Hospital of Harbin Medical University.
Investigation of the combined effects of cannabidiol plus naltrexone on alcohol craving in alcohol dependence: study protocol of a phase II randomised, double-blind, placebo-controlled, parallel-group trial - ICONICplus Trial.
BMJ Open
August 2025
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany.
Introduction: Alcohol dependence (AD) is highly prevalent and has severe consequences on health and quality of life. However, the efficacy of approved pharmacotherapies such as naltrexone (NTX) remains limited, highlighting the need for novel pharmacotherapeutic approaches. Cannabidiol (CBD) is a promising candidate, which has shown potential to reduce craving and alcohol use by modulating brain circuits involved in craving and addiction.
View Article and Find Full Text PDFEvaluation of the Safety and Efficacy of N-acetylcysteine in the Prevention of Paclitaxel-induced Peripheral Neuropathy: A Randomized, Double-blind, and Placebo-controlled Trial.
J Res Pharm Pract
June 2025
Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Institute of Herbal Medicines and Metabolic Disorders, Mazandaran University of Medical Sciences, Sari, Iran.
Objective: Paclitaxel-induced peripheral neuropathy (PIPN) is a disabling condition that leads to discontinuation or dose reduction of chemotherapy and reduces the patient's quality of life (QOL). We investigated the effect of N-acetylcysteine (NAC) in preventing PIPN.
Methods: This study was a randomized, double-blind, and placebo-controlled clinical trial conducted at a chemotherapy center of Mazandaran University of Medical Sciences.
Extended-release naltrexone versus oral naltrexone for substance use disorders: A systematic review and meta-analysis.
Drug Alcohol Depend
September 2025
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Purpose: This systematic review and meta-analysis aimed to compare extended-release naltrexone (XR-NTX) and oral naltrexone (NTX) for treating substance use disorders (SUDs).
Methods: A comprehensive search of multiple databases (MEDLINE, Embase, Cochrane, APA PsycInfo, and Scopus) was conducted on October 1, 2024, with no date or language restrictions. Inclusion criteria were adults with SUDs, interventions with XR-NTX, comparisons with oral NTX, and outcomes on treatment persistence, hospitalizations, and emergency department (ED) visits.